Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Standardizing hospital pharmacy practice in home hospitalization: results from a multidisciplinary Delphi consensus in Spain.

Frontiers in public health·2025
Same author

Impact on safety and cost of pharmaceutical interventions in the emergency department (INTERPHAR): a standardized methodology for multicenter documentation.

Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias·2025
Same author

PharmaCenter: Impact of post-discharge pharmaceutical carea consultation on medication-related problems in the emergenc department: A comprehensive analysis.

Research in social & administrative pharmacy : RSAP·2025
Same author

Improving medication safety in the perioperative setting: development of a medication use process.

British journal of anaesthesia·2025
Same author

Effects of a Pharmacist-Designed Clinical Decision Support System on Antimicrobial Stewardship.

Applied clinical informatics·2024
Same author

Perceived quality of life by patients with immune-mediated inflammatory diseases treated with biological therapies. SACVINFA study.

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria·2024

Related Experiment Video

Updated: May 20, 2026

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

[Emerging therapies for multiple sclerosis].

Ana de Lorenzo-Pinto1, Carmen Guadalupe Rodríguez-González, Arantza Ais-Larisgoitia

  • 1Servicio de Farmacia, Hospital General Universitario Gregorio Marañón, Madrid, España. ana.lorenzo@salud.madrid.org

Medicina Clinica
|July 7, 2012
PubMed
Summary

New multiple sclerosis (MS) treatments are emerging, offering improved efficacy and administration. This review details oral and monoclonal antibody therapies, highlighting their efficacy and safety profiles for managing MS.

More Related Videos

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis
05:44

Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis

Published on: October 13, 2023

Related Experiment Videos

Last Updated: May 20, 2026

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis
05:44

Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis

Published on: October 13, 2023

Area of Science:

  • Neuroimmunology
  • Clinical Pharmacology

Background:

  • Multiple sclerosis (MS) is a leading cause of disability in young adults.
  • Therapeutic advancements since 1993 have improved MS prognosis, yet few new drugs emerged recently.
  • Numerous clinical trials are underway, promising novel treatments with enhanced efficacy and administration schedules.

Purpose of the Study:

  • To review the main efficacy and safety results of emerging multiple sclerosis therapies.
  • To categorize new drugs into oral and monoclonal antibody classes.

Main Methods:

  • Review of efficacy and safety data for recently approved and pipeline MS drugs.
  • Classification of therapies into oral medications and monoclonal antibodies.

Main Results:

  • Emerging MS drugs aim for improved efficacy and convenient administration.
  • New safety concerns and economic impacts are anticipated with novel therapies.
  • Key oral therapies include fingolimod, laquinimod, teriflunomide, dimethyl fumarate, oral cladribine, and dalfampridine.
  • Prominent monoclonal antibodies include rituximab, ocrelizumab, ofatumumab, daclizumab, and alemtuzumab.

Conclusions:

  • The landscape of multiple sclerosis treatment is rapidly evolving with new oral and biologic therapies.
  • Careful evaluation of efficacy and safety is crucial for integrating these new options into clinical practice.
  • Anticipated safety issues and economic implications require careful consideration for healthcare systems.